<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<title>Immune Design's (IMDZ) CEO Carlos Paya on Q2 2015 Results - Earnings Call Transcript | Seeking Alpha</title>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name='viewport' content='width=1300'>


<meta http-equiv="x-dns-prefetch-control" content="on">
<link rel="dns-prefetch" href="//staticseekingalpha.a.ssl.fastly.net">
<link rel="dns-prefetch" href="//staticseekingalpha1.a.ssl.fastly.net">
<link rel="dns-prefetch" href="//staticseekingalpha2.a.ssl.fastly.net">
<link rel="dns-prefetch" href="//staticseekingalpha3.a.ssl.fastly.net">

<link href="//staticseekingalpha2.a.ssl.fastly.net/assets/favicon-46530755d46bb8a9005e583874cd8e5e.ico" rel="shortcut icon" type="image/ico">
<link rel="icon" type="image/png" href="//staticseekingalpha1.a.ssl.fastly.net/assets/favicon-16x16-09faeeb3fe8e97eb4b92edb8f904d792.png" sizes="16x16">
<link rel="icon" type="image/png" href="//staticseekingalpha2.a.ssl.fastly.net/assets/favicon-32x32-2208d73dfe9595e55f907c9ded5cc353.png" sizes="32x32">
<link rel="icon" type="image/png" href="//staticseekingalpha.a.ssl.fastly.net/assets/favicon-96x96-4f389eca45e750f5651a690469eb0af5.png" sizes="96x96">
<link rel="icon" type="image/png" href="//staticseekingalpha3.a.ssl.fastly.net/assets/favicon-192x192-6c9d478d320e913dc8644e519b4c1766.png" sizes="192x192">

<meta name="description" content="Immune Design (NASDAQ:IMDZ) Q2 2015 Earnings Conference Call August 12, 2015 04:30 PM ET Executives Shari Annes - IR Stephen Brady - EVP, Strategy and Finance C" /><meta name="keywords" content="NASDAQ:IMDZ" /><meta name="news_keywords" content="IMDZ, Immune Design, Healthcare, Transcripts, United States, Biotechnology" /><meta name="syndication-source" content="http://seekingalpha.com/article/3434746-immune-designs-imdz-ceo-carlos-paya-on-q2-2015-results-earnings-call-transcript"><link rel="canonical" href="http://seekingalpha.com/article/3434746-immune-designs-imdz-ceo-carlos-paya-on-q2-2015-results-earnings-call-transcript" />


<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"c0370b1d43","applicationID":"334927,334964","transactionName":"cldeEUAJWgldEBsASkVRUwlXFRkWUA1D","queueTime":1,"applicationTime":72,"agent":"js-agent.newrelic.com/nr-686.min.js"}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var o=n[t]={exports:{}};e[t][0].call(o.exports,function(n){var o=e[t][1][n];return r(o?o:n)},o,o.exports)}return n[t].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<t.length;o++)r(t[o]);return r}({QJf3ax:[function(e,n){function t(e){function n(n,t,a){e&&e(n,t,a),a||(a={});for(var u=c(n),f=u.length,s=i(a,o,r),p=0;f>p;p++)u[p].apply(s,t);return s}function a(e,n){f[e]=c(e).concat(n)}function c(e){return f[e]||[]}function u(){return t(n)}var f={};return{on:a,emit:n,create:u,listeners:c,_events:f}}function r(){return{}}var o="nr@context",i=e("gos");n.exports=t()},{gos:"7eSDFh"}],ee:[function(e,n){n.exports=e("QJf3ax")},{}],3:[function(e,n){function t(e){return function(){r(e,[(new Date).getTime()].concat(i(arguments)))}}var r=e("handle"),o=e(1),i=e(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(e,n){window.NREUM[n]=t("api-"+n)}),n.exports=window.NREUM},{1:12,2:13,handle:"D5DuLP"}],gos:[function(e,n){n.exports=e("7eSDFh")},{}],"7eSDFh":[function(e,n){function t(e,n,t){if(r.call(e,n))return e[n];var o=t();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,n,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return e[n]=o,o}var r=Object.prototype.hasOwnProperty;n.exports=t},{}],D5DuLP:[function(e,n){function t(e,n,t){return r.listeners(e).length?r.emit(e,n,t):void(r.q&&(r.q[e]||(r.q[e]=[]),r.q[e].push(n)))}var r=e("ee").create();n.exports=t,t.ee=r,r.q={}},{ee:"QJf3ax"}],handle:[function(e,n){n.exports=e("D5DuLP")},{}],XL7HBI:[function(e,n){function t(e){var n=typeof e;return!e||"object"!==n&&"function"!==n?-1:e===window?0:i(e,o,function(){return r++})}var r=1,o="nr@id",i=e("gos");n.exports=t},{gos:"7eSDFh"}],id:[function(e,n){n.exports=e("XL7HBI")},{}],G9z0Bl:[function(e,n){function t(){var e=d.info=NREUM.info,n=f.getElementsByTagName("script")[0];if(e&&e.licenseKey&&e.applicationID&&n){c(p,function(n,t){n in e||(e[n]=t)});var t="https"===s.split(":")[0]||e.sslForHttp;d.proto=t?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=d.proto+e.agent,n.parentNode.insertBefore(r,n)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=e("handle"),c=e(1),u=window,f=u.document;e(2);var s=(""+location).split("?")[0],p={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-686.min.js"},d=n.exports={offset:i(),origin:s,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),u.addEventListener("load",t,!1)):(f.attachEvent("onreadystatechange",r),u.attachEvent("onload",t)),a("mark",["firstbyte",i()])},{1:12,2:3,handle:"D5DuLP"}],loader:[function(e,n){n.exports=e("G9z0Bl")},{}],12:[function(e,n){function t(e,n){var t=[],o="",i=0;for(o in e)r.call(e,o)&&(t[i]=n(o,e[o]),i+=1);return t}var r=Object.prototype.hasOwnProperty;n.exports=t},{}],13:[function(e,n){function t(e,n,t){n||(n=0),"undefined"==typeof t&&(t=e?e.length:0);for(var r=-1,o=t-n||0,i=Array(0>o?0:o);++r<o;)i[r]=e[n+r];return i}n.exports=t},{}]},{},["G9z0Bl"]);</script>
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-status-bar-style" content="black">
<link rel="apple-touch-icon" sizes="57x57" href="//staticseekingalpha3.a.ssl.fastly.net/assets/apple/apple-touch-icon-57x57-a93a575c6dc6cfd0a797599e5a4aca43.png">
<link rel="apple-touch-icon" sizes="72x72" href="//staticseekingalpha2.a.ssl.fastly.net/assets/apple/apple-touch-icon-72x72-83db8db36f683647f2ea4912ef925672.png">
<link rel="apple-touch-icon" sizes="114x114" href="//staticseekingalpha3.a.ssl.fastly.net/assets/apple/apple-touch-icon-114x114-2dc61d132d5605efaec1fbc0f9928d87.png">
<link rel="apple-touch-icon" sizes="144x144" href="//staticseekingalpha.a.ssl.fastly.net/assets/apple/apple-touch-icon-144x144-71696df71f280a287129fa94bed7c653.png">
<link rel="apple-touch-icon" sizes="180x180" href="//staticseekingalpha.a.ssl.fastly.net/assets/apple/apple-touch-icon-180x180-d834ebf09d4ac710eba277348673886f.png">

<meta name="msapplication-config" content="//staticseekingalpha1.a.ssl.fastly.net/assets/ms/browserconfig-3991a8a2de372679027124c341359bf3.xml">
<meta name="msapplication-TileColor" content="#ff7200">
<meta name="msapplication-TileImage" content="//staticseekingalpha3.a.ssl.fastly.net/assets/ms/mstile-144x144-5156f086afb634519136fbe3bb36f435.png">
<link rel="icon" sizes="any" mask href="//staticseekingalpha2.a.ssl.fastly.net/assets/favicon-0e616d30d1102b37d7e06f1a53822ca1.svg">
<meta name="theme-color" content="#ffffff">

<meta property="og:locale" content="en_US">
<meta property="og:site_name" content="Seeking Alpha">
<meta property="og:title" content="Immune Design's (IMDZ) CEO Carlos Paya on Q2 2015 Results - Earnings Call Transcript">
<meta property="og:url" content="http://seekingalpha.com/earnings_center/all/article/3434746">
<meta property="og:image" content="//staticseekingalpha3.a.ssl.fastly.net/assets/social-50f1e86b5c7a0fda6a96bf2280e5360d.png">
<meta property="og:description" content="Immune Design (NASDAQ:IMDZ) Q2 2015 Earnings Conference Call August 12, 2015 04:30 PM ET Executives Shari Annes - IR Stephen Brady - EVP, Strategy and Finance Carlos Paya - President and CEO Analysts Matthew Andrews - Wells F">

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@SeekingAlpha">
<meta name="twitter:title" content="Immune Design's (IMDZ) CEO Carlos Paya on Q2 2015 Results - Earnings Call Transcript">
<meta name="twitter:image" content="//staticseekingalpha1.a.ssl.fastly.net/images/users_profile/000/101/639/big_pic.png?1361390405">
<meta name="twitter:description" content="Immune Design (NASDAQ:IMDZ) Q2 2015 Earnings Conference Call August 12, 2015 04:30 PM ET Executives Shari Annes - IR Stephen Brady - EVP, Strategy and Finance Carlos Paya - President and CEO Analysts">

<meta property="fb:admins" content="100006791796236" />

<link href="//staticseekingalpha1.a.ssl.fastly.net/stylesheets/packaged/performance_layout_packaged.css?h=1yw2rdg.css" media="screen" rel="stylesheet" type="text/css" /><link href="//staticseekingalpha.a.ssl.fastly.net/stylesheets/packaged/performance_layout_b_packaged.css?h=1b42syq.css" media="screen" rel="stylesheet" type="text/css" /><link href="//staticseekingalpha3.a.ssl.fastly.net/stylesheets/packaged/article_packaged.css?h=1ug2lsk.css" media="screen" rel="stylesheet" type="text/css" />
<!-- BEGIN Krux Control Tag for "seekingalpha.com" -->
<!-- Source: /snippet/controltag?confid=Jubkx3MY&site=seekingalpha.com&edit=1 -->
<script class="kxct" data-id="Jubkx3MY" data-timing="async" data-version="1.9" type="text/javascript">
    window.Krux || ((Krux = function () {
        Krux.q.push(arguments)
    }).q = []);
    (function () {
        var k = document.createElement('script');
        k.type = 'text/javascript';
        k.async = true;
        var m, src = (m = location.href.match(/\bkxsrc=([^&]+)/)) && decodeURIComponent(m[1]);
        k.src = /^https?:\/\/([a-z0-9_\-\.]+\.)?krxd\.net(:\d{1,5})?\//i.test(src) ? src : src === "disable" ? "" :
        (location.protocol === "https:" ? "https:" : "http:") + "//cdn.krxd.net/controltag?confid=Jubkx3MY"
        ;
        var s = document.getElementsByTagName('script')[0];
        s.parentNode.insertBefore(k, s);
    }());
    (function(){
    function retrieve(n){
        var m, k='kx'+n;
        if(window.localStorage){
            return window.localStorage[k] || "";
        }else if(navigator.cookieEnabled){
            m = document.cookie.match(k+'=([^;]*)');
            return (m && unescape(m[1])) || "";
        }else{
            return '';
        }
    }
    Krux.user = retrieve('user');
    Krux.segments = retrieve('segs') && retrieve('segs').split(',') || [];
    })();

</script>
<!-- END Krux Controltag -->





<script type="text/javascript">
  window.PAGE_START_TS = new Date().getTime(); //will be put in mone
  window.primaryMarketCap = 334352324;
  window.primaryTickerSlug = "imdz";
  var users_on_site='4,567,262';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="//staticseekingalpha.a.ssl.fastly.net/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  }

  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
    (function() {
      var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
      s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
      el.parentNode.insertBefore(s, el);
    })();

  var is_pro = false;


  var ASSET_HOSTS = ["//staticseekingalpha.a.ssl.fastly.net","//staticseekingalpha1.a.ssl.fastly.net","//staticseekingalpha2.a.ssl.fastly.net","//staticseekingalpha3.a.ssl.fastly.net"];
</script>
<script crossorigin="use-credentials" src="//staticseekingalpha1.a.ssl.fastly.net/javascripts/packaged/common_packaged.js?h=yf1htn.js" type="text/javascript"></script>
<script crossorigin="use-credentials" src="//staticseekingalpha2.a.ssl.fastly.net/javascripts/packaged/common2_packaged.js?h=1yekw1o.js" type="text/javascript"></script>
<script crossorigin="use-credentials" src="//staticseekingalpha1.a.ssl.fastly.net/javascripts/packaged/coffee_packaged.js?h=1a31cfu.js" type="text/javascript"></script><script crossorigin="use-credentials" src="//staticseekingalpha.a.ssl.fastly.net/javascripts/packaged/common_article_packaged.js?h=jobbp6.js" type="text/javascript"></script>  <script src="//staticseekingalpha.a.ssl.fastly.net/memcached2/symbol_rt_data"></script>

      <script>
      if (!SA.Utils.SASource.didInitialWithEmailInUrl()) {
        document.write('<scr'+'ipt src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></scri'+'pt>');
      }
    </script>
<script>
  var adata = SA.Data.Cache.get('campaign_content');
</script>

        <script id="liftigniter-metadata" type="application/json">
      {
        "author_name": "SA Transcripts",
        "author_image": "//staticseekingalpha1.a.ssl.fastly.net/images/users_profile/000/101/639/big_pic.png?1361390405",
        "id": "3434746",
        "primary_ticker": "imdz",
        "published_time": "2015-08-12 19:47:09 -0400",
        "publish_time": "2015-08-12 19:47:09 -0400"
      }
    </script>
    <script>
  (function(w,d,s,p,v,e,r) {w['$petametrics_var']=v;w[v]=w[v]||function(){(w[v].q=w[v].q||[]).push(arguments)};w[v].l=1*new Date();e=d.createElement(s),r=d.getElementsByTagName(s)[0];e.async=1;e.src=p;r.parentNode.insertBefore(e,r)})(window,document,'script','//cdn.petametrics.com/p.js','$p');
  $p("init", "k2lfmn21cq6srufb");
  $p("send", "pageview");
</script>
<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}

window.siteon=true;window.acounter=0;//temporary, tell Ilya to delete
</script>
<style>
#embd_slider{
display:none;
}
#top_gainers_wrap .data_currencies_table table {
  width: 100%;
}
#follow_wrap {
  width: 640px;
}

#pro_by_ticker li a {
  max-width:500px;
}
</style> 
<script>
 if (SA && SA.Data && SA.Data.User){
		SA.Data.User.authorResearch = function(){
    return readCookie('author_research_subscriptions') ? readCookie('author_research_subscriptions').split(',') : [];
  }
}
</script>
        </head>
  
  <body class="stretch_bg">

    <script>
  var ms_slug = '';
  var article_dashboards = 'transcript';
  var article_sectors_themes = '@transcripts@us@biotechnology@healthcare@article@';
  var ratings_hash={}
  var ARTICLE_ID = 3434746 ;
  var ARTICLE_TYPE = 'transcript';
  var ARTICLE_LOCK = "";
  var availableABVersions=["ver_a"];
  var abOBJ = new ABTest('transcript_pagination', availableABVersions);
  var machine_id = cookieExists('machine_cookie') ? parseInt(readCookie('machine_cookie')) : 0;
  var abVersion = abOBJ.value;
  var sliceSize = 4000;
  var isTranscript = true;
  var insight_sector = null;
  var isWebcast = false;
  var middle_version = ABTest.identity%10;
  var author_tag_id = 96991;
  var author_slug = "sa-transcripts";

  try {window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');}
  catch (error) {}
</script>
<script>var mone_article_tags = "{imdz};;;{healthcare};;;{transcripts,us,biotechnology};;;{sa-transcripts}"</script>

<script>var ord = Math.floor(Math.random() * 1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (SA.Data.Cookies.get('show_desktop') == '1') {
    var aHTML = [];
    aHTML.push('<div class="mobile_or_full_site">');
    aHTML.push('<span class="mobile_site" onclick="backToMobile();">Click here to view mobile site</span>');
    aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
  function backToMobile() {
    SA.Data.Cookies.del('show_desktop');
    var url = window.location.href;
    if (url.indexOf('?') > -1){
      url += '&source=show_desktop_false';
    }else{
      url += '?source=show_desktop_false';
    }
    window.location.href = url;
  }
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <div class="logo_and_menu_section">
      <div id="header_dropdown">
        <a href="/" id="sa_logo" title="Seeking Alpha" sasource="salogo"></a>
        <div class="header_arrow caret"></div>
        <div class="hdd_wrapper" itemscope="" itemtype="http://schema.org/SiteNavigationElement" role="navigation"><div class="hdd_arrow"></div><ul class="hdd_menu hdd_insights themes"><li class="hdd_header">THEMES</li><li itemprop="name"><a href="http://seekingalpha.com" itemprop="url" sasource="headtab_menu" title="Home">Home</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/insight/alternative-investing" itemprop="url" sasource="headtab_menu" title="Alt Investing">Alt Investing</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/insight/dividend-investing" itemprop="url" sasource="headtab_menu" title="Dividend Investing">Dividend Investing</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/earnings_center" itemprop="url" sasource="headtab_menu" title="Earnings Center">Earnings Center</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/etf_hub" itemprop="url" sasource="headtab_menu" title="ETF Hub">ETF Hub</a></li><li class="hdd_sep"></li></ul><ul class="hdd_menu hdd_insights"><li class="hdd_header">&nbsp;</li><li itemprop="name"><a href="http://seekingalpha.com/insight/income-investing" id="income_tab" itemprop="url" sasource="headtab_menu" title="Income Investing">Income Investing</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/analysis/investing-ideas" itemprop="url" sasource="headtab_menu" title="Investing Ideas">Investing Ideas</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/analysis/macro-view" itemprop="url" sasource="headtab_menu" title="Macro View">Macro View</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/analysis/etf-portfolio-strategy" itemprop="url" sasource="headtab_menu" title="Portfolio Strategy">Portfolio Strategy</a></li></ul><ul class="hdd_menu hdd_premium" id="hdd_my_account"><li class="hdd_header">MY ACCOUNT</li><li itemprop="url"><a href="http://seekingalpha.com/account/email_preferences" itemprop="name" sasource="topnav_mouseover" title="Email Settings">Email Settings</a></li></ul><ul class="hdd_menu hdd_premium"><li class="hdd_header">PREMIUM</li><li class="premium_sub_header" itemprop="name"><a href="http://seekingalpha.com/pages/premium_authors" itemprop="url" rel="nofollow" sasource="headtab_menu" title="Premium Authors">Premium Authors</a></li><li><ul class="premium_nav_list"><li itemprop="name"><a href="http://seekingalpha.com/pages/premium_authors?sort=p&amp;order=d" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Most Popular">Most Popular</a></li><li itemprop="name"><a href="http://seekingalpha.com/pages/premium_authors?sort=n&amp;order=d" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Newest">Newest</a></li></ul></li><li class="hdd_sep"></li><li class="premium_sub_header" itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="headtab_menu" title="PRO">PRO</a></li><li><ul class="premium_nav_list"><li itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Top Ideas">Top Ideas</a></li><li itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="First Look">First Look</a></li><li itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Idea Filter">Idea Filter</a></li></ul></li></ul></div>      </div>
      <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont" >
      <ul id="navi" class="navi">
        <li id='author_research_top_nav' style='display:none'>
          <div id="authors_dropdown">
            <a>My Authors</a>
            <div id="authors_wrapper" class="authors_wrapper"/>
          </div>
        </li>

        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs">Portfolio
            <span id='portfolio_notifications'></span>
          </a>
        </li>
            <li thistab='market_news'>
              <a href="http://seekingalpha.com/news/all" sasource="headtabs">News</a>
            </li>

            <li thistab='analysis'>
              <a href="http://seekingalpha.com/analysis/all" sasource="headtabs">Articles</a>
            </li>

            <li thistab='stocktalks'>
              <a href="http://seekingalpha.com/stocktalks/all" sasource="headtabs">StockTalk</a>
            </li>
        <li thistab='marketplace' id='menu_marketplace_tab'>
          <a href="http://seekingalpha.com/pages/premium_authors" sasource="headtabs" style="display: none" rel="nofollow">Marketplace</a>
        </li>

        <li thistab='pro' class="pro_tab" id="nav_pro_tab">
          <a href="http://seekingalpha.com/account/pro" sasource="headtabs" rel="nofollow">PRO</a>
        </li>

        <li class="right_section">
          <div class="" id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>


  <div style='display:none' class="rta_nav etf_hub">
    <span class="rta_nav_wrap">
      <div>To screen ETFs by asset class, performance, yield and more, check out the <a href="/etf_hub" sasource="etf_performance" >ETF Hub.</a> <a  sasource="etf_performance" href="/etf_hub" id="etf_hub_button">ETF Hub</a></div>
    </span>
  </div>
</div>

    </div>

    <div class="info_and_search_section" id="right_menu">
      <div id="nav_user_settings"></div>
      <div id="site_search">
        <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="Search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='Search by symbol, author, keyword...' class="find_transcripts" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" id="autocomplete_sa_hidden_avoid_symbol" name="avoid_symbol" value="" />
      <input type="hidden" name="sort" value="date:d" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, Keywords:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="//cse.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>

      </div>
    </div>
    <div class="clearfix"></div>
  </div>
  <script type="text/javascript">
      SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>

<div id="main_container" class="center_pro transcript_page">
    <script>
      if(window.screen.availWidth > 1260 || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) $('main_container').addClassName('show_left_cont');
    </script>
     <div class='left_cont'>
            <div id="left_top_ad"></div>
        <div class="stickyad_wrapper">
          <div class="item banner160x600" id="fixed_banner160x600"></div>
					 <script type="text/javascript">
							var didCreateAd = false;
              function setAD(){
               if (didCreateAd) return;

							    SA.Utils.Ads.GoogleTag.define("/6001/sek.earnings/reports", [[160,601]],'left_top_ad', {"sz":"160x601","x":["x","x"],"tile":1,"d":["earnings","sectors"],"t":["reports","transcripts","us","biotechnology","healthcare","article"],"aid":3434746,"z":1,"a":"sa-transcripts","cnt":["20","24","38","37","41"],"pr":"imdz","s":"imdz"});

								SA.Utils.Ads.GoogleTag.define("/6001/sek.earnings/reports", [[160,600]],'fixed_banner160x600', {"sz":"160x600","x":["x","x"],"tile":3,"d":["earnings","sectors"],"t":["reports","transcripts","us","biotechnology","healthcare","article"],"aid":3434746,"z":1,"a":"sa-transcripts","cnt":["20","24","38","37","41"],"pr":"imdz","s":"imdz"},{sticky: true});

                Mone.article_shown_left_ad = true;
								didCreateAd = true;
              }
              if(window.screen.availWidth > 1260 || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) setAD();
           </script>
        </div>
          </div>
  <div id="content_wrapper" itemscope itemtype="http://schema.org/Article" class="article_pages">
    <img src="//staticseekingalpha.a.ssl.fastly.net/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
     <div id="main_content" class='no_big_gaps_main_content'>
      <div id="" class="no_big_gaps_secondary_ads">
        <div id='article_top_info'>
    <a href='/author/sa-transcripts' sasource='auth_header_pic'><img id='author_info_img' class="author_img" align="center" src="//staticseekingalpha1.a.ssl.fastly.net/images/users_profile/000/101/639/big_pic.png?1361390405" width="66px" height="66px" /></a>
    <div class='info_content'>
      <div>
        <a itemprop="author" class='author_name' href='/author/sa-transcripts' id='author_info_name' rel='author' sasource='auth_header_name'>SA Transcripts</a>,
            <span  >
              <a class='author_nick link' href="http://seekingalpha.com/analysis/transcripts/all?source=article_author_top" target='_blank' onclick='if (!/@seekingalpha.com/.test(SA.Data.User.email())) Mone.event("article", "auth_header_link", "click", {data: {"url":"http://seekingalpha.com/analysis/transcripts/all","text":"Recent earnings call transcripts","author_id":44211,"name":"SA Transcripts","bio":"We cover over 5K calls/quarter"}})'>
                Recent earnings call transcripts
              </a>
            </span>
          <span class="clicks">(44,150 clicks)</span>
      </div>
      <div>
        <span class='author_desc'>We cover over 5K calls/quarter</span>
      </div>
      <div class="bottom_line">
        <a href='/author/sa-transcripts' sasource='auth_header_profile' class="author_action">Profile</a><span class='sep'>|</span>
        <span class='author_action' onclick='Messaging.sendMessagePopup("1aoxskmd","article_auth_header")'>Send Message</span><span class='sep' id='hider'>|</span>
        <div id="mover" class="di">
          <span id="rollover_menu" style="display: none;" onmouseleave="ArticlePage.hideRolloverMenu()">
            <div class="arrow"></div>
            <span id="rollover_content">
              <div class="rta_bottom">
                <div class="m_pop point_left" id="promotion_box_rel">
                  <div id="close_rollover" class="tr cp pr10 pt2">x</div>
                    <div class="m_pop_inner">
                      <div class="popup_header">Author Following Options:</div>

                      <div class="premium_research_header" style='display:none'>
                        <div class="popup_row_header">
                          <div class="preloader_popup_ab" style="float: left;">
                            <input type="checkbox" id="author_research_learn_more" class="author_research_check" style="margin-right: 5px;">
                          </div>
                          
                        </div>
                        <div class="popup_row_footer">
                          &nbsp;<a class="bold" target='_blank' sasource='follow_top_learn_more' href="/account/research/subscribe?slug=sa-transcripts&source=follow_top_learn_more">Learn more»</a>
                        </div>
                      </div>

                      <div class="popup_row_first">
                            <div class="popup_row_header">
                              <div class="preloader_popup_ab" style="float: left;">
                                <input type="checkbox" id="follow_author_checkbox" style="margin-right: 5px;">
                              </div>
                              Follow this author
                            </div>
                          <div class="popup_row_footer">See their articles on your Seeking Alpha homepage and in your feed.</div>
                        </div>
                        <div class="popup_row_second">
                          <div class="popup_row_header">
                            <div class="preloader_popup_ab" style="float: left;">
                              <input type="checkbox" id="get_rta_author_checkbox" style="margin-right: 5px;">
                            </div>
                            <div id="max_rta_header">Real-time alerts on this author</div>
                          </div>
                          <div id="max_rta_footer" class="popup_row_footer">Get their new articles emailed to you as they are published.</div>
                        </div>
                        <div class="popup_row_last">
                          <div class="popup_row_header">
                            <div class="preloader_popup_ab" style="float: left;">
                              <input type="checkbox" id="subscribe_digest" style="margin-right: 5px;">
                            </div>
                            Daily digest on all my authors
                          </div>
                          <div class="popup_row_footer">Get all your favorite authors’ new articles emailed to you in one daily digest.</div>
                        </div>
                    </div>
                  <div class="cleaner"></div>
                </div>
              </div>
            </span>
          </span>
          <span id="msg_popup"></span>
          <span id='follow_btn' class="follow_button_author" onclick="ArticlePage.toogleFollowAuthor('article_auth_header')" onmouseover="ArticlePage.showRolloverMenu()"></span>

          <span id="ballon_container"></span>

          <span id="follow_only_top"></span>
          <span class='clicks'>
            (<span id='follow_clicks' class='follow_clicks_author'>6,669</span> followers)
          </span>
        </div>
      </div>
      <div class='arr_up'></div>
    </div>
    <script>
      setArticleTopABTest();
      SA.Pages.Article.Follow.init('sa-transcripts');


      Mone.articleAuthorLinkShown = true;

      function setEvents(){
        var marketing_unit = $('author_research_learn_more');
        if (marketing_unit) marketing_unit.observe('click', listEvents);
      }

      function listEvents(e){
        if (e.target.hasClassName('author_research_check')){
          SA.Utils.SASource.setNext('follow_top');
          window.open("/account/research/subscribe?slug=sa-transcripts&source=follow_top", '_blank' );
          if (e.target.checked) e.target.checked = false;
        }
      }

      function setArticleTopABTest(){
        if (!window.is_active_research_author || !$('article_top_info') || SA.Data.Cookies.get('author_slug') == window.author_slug) return;

        var test_value = ABTest.tenth, test_version, author_name = $('author_info_name').innerHTML, subscribe_link = '/account/research/subscribe?slug='+ window.author_slug + '&source=article_top_author_banner';
        $$('#article_top_info .info_content div')[0].update($('author_info_name').cloneNode(true));

        if (test_value){
          test_version = 'ver_1';
          $$('#article_top_info .info_content div')[0].insert("<a class='premium_research_button' href='"+subscribe_link+"'>Premium Research &raquo;</a>");
        }
        $('article_top_info').addClassName(test_version);
      }

      SeekingAlpha.Initializer.onDOMLoad(function(){ setEvents();});

    </script>
</div>




      </div>
       <div id='top_author_details'>
         <div id="article_header" class="article_content">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="headline">Immune Design&#x27;s (IMDZ) CEO Carlos Paya on Q2 2015 Results - Earnings Call Transcript</span>
              </h1>
      <div id="article_info">
        <div class="article_info_pos">
          <span itemprop="datePublished" content="2015-08-12T23:47:09Z">Aug. 12, 2015  7:47 PM ET</span>
          <span id='title_article_comments'></span>
          <span class="print_hide"><span class='print_hide'>&nbsp;|&nbsp;</span> <span>About:</span> <span id='about_primary_stocks'><a href="/symbol/IMDZ" title='Immune Design' sasource='article_primary_about_trc'>Immune Design (IMDZ)</a></span></span>
          <span class="author_name_for_print">by: SA Transcripts</span>
            <span id="second_line_wrapper"></span>
        </div>
        <div class="article_disclosure">
          <div id="article_body_top2" class="disclosure_top" style="display:none;"></div>
        </div>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>

       </div>
        <div id="article_body_container" class="no_big_gaps_article_body_container">
          <div id="article_body" itemprop="articleBody">
            <div id="article_participants" class="content_part hid">
  <p>Immune Design (NASDAQ:<a href='http://seekingalpha.com/symbol/imdz' title='Immune Design'>IMDZ</a>)</p>
<p>Q2 2015 Earnings Conference Call</p>
<p>August 12, 2015 04:30 PM ET</p>
<p><strong>Executives</strong></p>
<p>Shari Annes - IR</p>
<p>Stephen Brady - EVP, Strategy and Finance</p>
<p>Carlos Paya - President and CEO</p>
<p><strong>Analysts</strong></p>
<p>Matthew Andrews - Wells Fargo Securities</p>
<p>Biren Amin - Jefferies</p>
<p>Boris Peaker - Cowen &amp; Company</p>
</div>

<div id="article_content" class="content_part hid">
  <p><strong>Operator</strong></p>
<p>Good afternoon and thank you for joining Immune Design’s Second Quarter 2015 Conference Call. At this time, all participants are in a listen-only mode. Following management’s remarks, we will hold a brief question-and-answer session and at that time, the lines will be open for you.</p>
<p>I would now turn the call over to Shari Annes, Immune Design’s Investor Relations. Please go ahead.</p>
<p><strong>Shari Annes </strong></p>
<p>Good afternoon and welcome to Immune Design’s second quarter 2015 financial results conference call. Our goal is to outline the quarter’s financial results, and update you on the Company’s clinical progress. We will also provide perspective on the three new collaborations with Merck and Genentech that we announced this week, especially as underscore the opportunities inherent to our immuno-oncology strategy. Copies of this week’s press releases are available in the Investor Relations section of the company’s website at www.immunedesign.com. Today’s call is being recorded and will be available for replay shortly after the call for 90 days as well as in the Investor Relations section of the company’s website.</p>
<p>Joining me on the call today from Immune Design are Dr. Carlos Paya, President and Chief Executive Officer; and Mr. Stephen Brady, EVP Strategy &amp; Finance. For the Q&amp;A portion of the call Mr. Chris Whitmore, Vice President of Finance and Administration will join us.</p>
<p>Before we start, I would like to remind you that today’s call will include forward-looking statements based on current expectations. Forward-looking statements contained on this call include, but are not limited to, statements about the expected mechanisms and the results of CMB305 and G100, the timing of commencement of results to design and the data from our current and future clinical trial and the company’s future financial results. Such statement represents management’s judgment and intention as of today and involved assumptions, risks and uncertainties. Immune Design undertakes no obligation to update or revise any forward-looking statement. Please refer to Immune Design’s filings with the SEC, which are available from the SEC or on the Immune Design website for information concerning the risk factors that could affect the company.</p>
<p>I’ll now turn the call over to Steve.</p>
<p><strong>Stephen Brady</strong></p>
<p>Thank you, Shari. Good afternoon everyone and welcome to our second quarter 2015 earnings call. I will discuss our financial results for the second quarter and then I will turn the call over to Carlos who will provide a company update and discuss the successful execution of our near-term immuno-oncology strategy.</p>
<p>Turning to our financial results, during the second quarter of 2015 we reported a net loss of 10.5 million or $0.54 per share compared to 6.1 million or $16.57 per share for the second quarter of 2014. In addition to higher operating expenses the wide range in our loss per share numbers is due to both the comparison of quarters pre and post IPO and subsequent follow-on financing and the reverse stock split associated with the IPO as well as the new shares issued in the IPO and subsequent follow-on offering. </p>
<p>The increase in our net loss this quarter compared to the same period in 2014 was primarily attributable to an increase of operating expenses partially offset by an increase in revenues. </p>
<p>Revenue for the second quarter of 2015 was 1.8 million primarily generated from our collaboration with Sanofi Pasteur for the development of a vaccine therapy for the herpes simplex virus known as G103. Revenue for the second quarter of 2014 was 1.1 million and related primarily to licensing revenue. Total operating expenses for the second quarter of 2015 were 12.3 million compared to 5.8 million for the second quarter of 2014. </p>
<p>R&amp;D expenses were 8.5 million for the second quarter of 2015 compared to 3.9 million for the second quarter of 2014. The 4.6 million increase in R&amp;D primarily related to contract manufacturing and clinical trial cost as well as activities related to the HSV-2 collaboration with Sanofi Pasteur for which we are almost entirely reimbursed and reflect those reimbursements as revenues.</p>
<p>We also had an increase in personnel relating expenses including stock-based compensation as a result of growth in R&amp;D headcount to support our advancing of research and clinical pipeline. </p>
<p>G&amp;A expenses for the second quarter were 3.8 million compared to 1.9 million for the second quarter of 2014. This increase of 1.9 million was primarily attributable to increases in personnel related expenses including stock-based compensation and to support growth and expansion of our business following our initial public offering in July of last year.</p>
<p>I would also like to briefly summarize our year-to-date financial results. Net loss and net loss per share for the six months ended June 30, 2015 were 19.9 million and the $1.10 compared to 14.3 million and $38.81 for the same period in 2014. Quite similar to the quarter-to-date comparison of our net loss, the net loss for year-to-date has increased primarily due to an increase in R&amp;D activities and an increase in general and administrative expenses to support our operations as a public as well as the change in capitalization of the company. </p>
<p>Lastly, I would like to discuss our cash position and provide updated guidance for the current year. As you may recall in April of this year we closed our follow-on equity offering which resulted in net proceeds to the company of 75.4 million. With the addition of this funding as well as funding from our IPO we ended the current quarter with 129 million which represents an increase of over 53 million from our 2014 yearend balance.</p>
<p>The progress in our programs and the additional capital support the development of our growing clinical pipeline and next generation product candidate and provides us adequate funding at least well into 2017 based on our current operating plan. </p>
<p>During our year-end conference call held in March, we projected 2015 net cash used in operating activities to be between 33 million and 37 million. In consideration of the follow-on offering and planning for increased clinical trials activity we are taking this opportunity to revise our guidance and expect to end 2015 with a cash and investments balance of at least the 110 million and project net cash used in operating activities of 36 million to 40 million. </p>
<p>Before I turn the call over to Carlos I also wanted to mention that we filed the self-registration on Form S-3 earlier today. This does recovers the sale of up to 250 million in common stock and because we recently passed our one-year mark as a public company and became eligible to file we view this as good corporate housekeeping. </p>
<p>With that I’ll turn the call over to Carlos.</p>
<p><strong>Carlos Paya</strong></p>
<p>Thank you, Steve and good afternoon to everyone. I would like to take this opportunity to share Immune Design’s progress during the first half of this year and put into perspective how this achievement position us to execute our product development plans within our immuno-oncology strategy. The goal of our product candidate is to effectively and safely trigger our durable immune response against the patient’s tumor which should ultimately modify the course of cancer. This is different than the mechanism of action of checkpoint inhibitors of the PD-1, PL-1 active, which thought leaders believe mainly work when the treated patient has a pre-existing anti-tumor immune response. </p>
<p>Depending on the tumor type we believe roughly half to two thirds of treated patients either experience progressive disease or achieve stable disease as their best response to checkpoint inhibitors. And this is believed to be due to the lack of an anti-tumor immune response. </p>
<p>Hence our immune oncology strategy is to develop our compounds at single agents and in combination with checkpoint inhibitors. Our rational expectation is that combination of agent that trigger a durable anti-tumor immune response such as those that we are developing with checkpoint inhibitor products will be additive if not synergistic, thereby enlarging the proportion of patients that will respond to checkpoint inhibitors of the PD1 and PD-L1 act.</p>
<p>So let me now cover the progress made around our product candidates. CMB305 and G100 are our two product candidates under clinical development aimed at triggering an anti-tumor immune response. In contrast to other T cell based approaches that require individualize ex vivo manipulation, both of our products are designed to be off the shelf therapies that work in-vivo by directly generating and/or expanding anti-tumor killer cytotoxic T cells and other immune effector cells.</p>
<p>CMB305 is designed to trigger and maintain a durable systemic T cell immune response against NY-ESO-1, a tumor antigen expressed in large number of cancers. In contrast G100 when given intratumorally is designed to activate T cells directed against multiple tumor antigens recognized within the tumor. Since our IPO a year ago, we have been diligently executing our clinical development plan which we have described as &quot;building the blocks&quot; of this potential therapy.</p>
<p>As such CMB305 is a combination of two blocks, LV305 and G305. Each block was evaluated in separate Phase 1 trials to test that each agent would individually activate different arms of immune response against the NY-ESO-1 antigen expressed in the tumor. Likewise, G100 was also evaluated in combination with local radiation as the latter lightest tumor cells that maximized the chance of G100 to generate and activate a broad repertoire of T cells recognizing antigen expressing within the tumor.</p>
<p>At the May 2015 ASCO meeting we presented three separate Phase 1 studies that support the further development of both CMB305 and G100. In the two LV305 and G305 Phase 1 studies the blocks of CMB305 we saw; number one, a pivotal safety profile with only grade one to two adverse events; number two, predicted immunogenicity for each of the two components in the form of the generation of NY-ESO-1 specific, CD4 T cells and antibodies for G305 and of NY-ESO-1 specific CDA and CD4 T cells for LV305; and three, signals of clinical benefit in the form of stabilities, biomarker reduction in the sarcoma patients, a progression of fee rate that compares favorably with historical references for active sarcoma. We believe that the data from each component justifies their combination into the single product candidate named CMB305. </p>
<p>Separately in patients with Merkel cell carcinoma treated with G100, a potent healer for agonist, intra-tumorally we also reported a favorable safety profile with only grade one to two adverse events and then overall response rate of 50% for treatment protocol in the first eight patients. We also observe evidence that G100 had effect at monotherapy and that mechanistically it enhances and expands antitumor cytotoxic T cells present within the tumor, altogether also supporting the further development of G100. With this initial validation we’re now moving forward with the development of both CMB305 and G100 into later stage studies alone and in combination with checkpoint inhibitors of the PD-L1, PD1.</p>
<p>Let me discuss briefly LV305 because although we’re currently not intending to develop it as a single agent while we ramp up the further development of CMB305 we are completing an expansion cohort of LV305 beyond the dose escalation Phase 1 in soft tissue sarcoma patients that we reported at ASCO. The goal is twofold; one is to gather further knowledge regarding the safety and immunogenicity when administered at the highest dose in patients with sarcoma, ovarian and lung cancer; and two, start exploring its potential when combined with checkpoint inhibitors in patients with melanoma. The latter goal will be facilitated with the agreement we’ve just announced with Merck in which LV305 will be studied in combination with KEYTRUDA.</p>
<p>Merck’s PD1 inhibitor in melanoma patients who have not responded to treatment with checkpoint inhibitors [study] PD1. This will allow us to start exploring the possible synergy between an agent that triggers an antitumor immune response, such as LV305 and an effective inhibitor of the PD-L1, PD1 actives like KEYTRUDA. </p>
<p>Regarding our CMB305 product candidate which is a sequential combined administration of LV305 and G305, we have successfully completed the dose escalation of this compound. The mid and highest dose level of LV305 were tested with the mid dose level of G305 into separate patient cohorts respectively demonstrating our favorable safety profile in each cohort. Based on this, we are now embarking on an expansion cohort study using the highest dose to determine its safety and immunogenicity in a larger patient population of soft tissue sarcoma, ovarian and lung tumors expressing NY-ESO-1 and importantly planning for our Phase 2 randomized trial in patients with NY-ESO-1 positive soft tissue sarcomas as our initial potential very efficient indication. </p>
<p>This randomized Phase 2 trial contemplates interaction of an anti-PD-L1 inhibitor compound in combination with our CMB305, because there are no checkpoint inhibitors approved today for the treatment of sarcoma we were pleased to announce this morning that we signed a clinical collaboration agreement with Genentech, under which Genentech will provide its investigational anti-PD-L1 therapy at atezolizumab also known at MPDL3280A for this important trial. </p>
<p>The randomized Phase 2 study being planned is expected to evaluate the safety and efficacy of CMB305 in combination with atezolizumab versus atezolizumab alone with patients with locally advanced, relapsed or metastatic soft tissue sarcoma expressing NY-ESO-1.</p>
<p>Now moving on to G100 let me provide you an update regarding intra-tumoral immune activation approach with our clinical candidate G100. Immune Design recently completed enrollment of their pre-certified temptations in its Phase 1 clinical trial of G100 in patients with Merkel cell carcinoma beyond those eight patients presented at ASCO.</p>
<p>Based on the encouraging clinical response of 13 dispersing patients we are expanding this approach into our Phase 1, 2 trial evaluating G100 in patients with non-Hodgkin lymphoma or NHL. </p>
<p>Although mechanistically it is different from CMB305, G100 is also designed to illicit from CD8 T cell response against the tumor. Therefore in the same NY-ESO-1 CMB305 we believe which is also synergized with a checkpoint inhibitor and we have been considering a trial combining G100 with a checkpoint inhibitor with PD-L1, PD1x. To achieve this goal and in addition to the Merck agreement to combine Keytruda with LV305 in patients discussed earlier we have signed a second agreement with Merck to combine Keytruda with G100 in a planned NHL study.</p>
<p>Here our goal is to determine whether local administration of G100 and low radiation with or without Keytruda will cause a seismic anti-tumor immune response resulting in clinical benefit in both the treated and the untreated non-Hodgkin lymphoma tumors.</p>
<p>In conclusion we believe that Immune Design through its continued execution of its immuno-oncology strategy is in a stronger position that we were at the beginning of this year. One, we have now clinical data to support the scientific rational behind both of our two product candidates G100 and CMB305. </p>
<p>Number two; we are pleased to be working with two leading biopharma companies in the field of immuno-oncology Merck and Genentech in three separate studies across both of Immune Design approaches.</p>
<p>And third, more importantly we are now in a position to validate the fundamental hypothesis that combining cutting edge technologies designed to trigger an antitumor immune response in vivo with inhibitors of the PD-L1, PD1 should be additive if not synergistic and that enhanced the potential therapeutic of these two key pillars of immuno-oncology. </p>
<p>In terms of news flow by the end of the year we expect to have data from the ongoing LV305 single agent expansion study. Number two, have complete data from the two cohorts of the CMB305 Phase 1b dose escalation trial as well as preliminary data from our single seeking expansion arm for CMB305.</p>
<p>Number three, have complete data from the completely enrolled G100 Phase 1 trial in Merkel cell carcinoma patients. Number four, have initiated two studies with Merck's Keytruda one in combination with LV305 in melanoma patients and our second NHL study of G100 in combination with Keytruda in patients with NHL. </p>
<p>And number five; have initiated a randomized Phase 2 study for CMB305 with [additional lucemab] in patients with soft tissue sarcoma. With this expected data and achievement in hand we expect to be poised to continue to execute on our strategy to become a core and differentiated company in the field of immuno-oncology. The potential synergy of combining our compounds that triggered an anti-tumor immune response with checkpoint inhibitors of the PD1/PD-1 access in our major near term goal because potentially it can greatly expand efficacy and reach of such checkpoint inhibitors.</p>
<p>In additions our compound and technologies maybe applicable to enhance other approaches in these exciting field of immuno-oncology that require in vivo generation expansion of anti-tumor T-cells.</p>
<p>In summary, we are very pleased with our progress to-date and look forward to continuing the execution of our immuno-oncology strategy. I’d now like to turn the call over to your questions and operator if you can help us from your end. Thank you.</p>
</div>

<div id="article_qanda" class="content_part hid">
  <p><strong>Question-and-Answer Session </strong></p>
<p><strong>Operator</strong></p>
<p>Yes, sir. [Operator Instructions]. And our first question comes from the line of Matthew Andrews from Wells Fargo Securities. Your line is open.</p>
<p><strong><span class="question">Matthew Andrews</span></strong></p>
<p>Carlos, can you just go back through the comments you made relative to the data you have in house for CMB305 for the dose escalation cohorts the six patients? Second question, you’ve provided some update on the second generation antivirus vector where that program stands and potential differentiating characteristics versus your current vector? And then three, there has been some new data out of Memorial Sloan-Kettering which suggests expression of PD-L1 in sarcoma maybe a little bit lower than the [KIM] data in Korean patients that you’ve discussed. So I was just curious, I know it’s far challenging across comparing different datasets, but I was curious your thoughts around the PD-L1 expression in sarcoma and if these new data change, how you think your agents along with PD-L1 inhibitor will play out? Thanks.</p>
<p><strong><span class="answer">Carlos Paya</span></strong></p>
<p>I’ll start with your first question, which is the data that we’re having is safety, we have to your point enrolled six different patients, three at the mid dose LV305 with mid dose of G305 and the third next cohort we included the additional three more patients with the highest dose of LV305 and G305. All those three patients are soft tissue sarcomas are of course all of them expressing NY-ESO-1 and the SMB allowed us to go from that initial cohort to the second cohort based on safety or lack of safety findings. And again once more collaborated the lack of finding safety wise with the highest cohort.</p>
<p>And therefore based on that, we have elected to move as I mentioned before on the expansion study in more patients also including not just in this case tissue sarcoma but the other two tumor types. And so what we have right now is we are actively enrolling the dose expansion and that’s why we will be now collecting all the immunogenicity data and clinical data from the follow up of these patients and that’s the data we intent to have available to be able to share by hopefully the end of the year really.</p>
<p>Regarding the second question which is the second generation ZVex, we are very excited by being one of the unique companies during these prime boost approach which as you know requires a vector like the one we have which is dendritic cells tropic to expand and generate T cells from scratch but then also have a boost that will then maintain those T cells as durable and long lasting which I think is -- we are running a marathon, it's not just a short race, so you need to have these cells really being there kind of reactivated on a constant basis. So what we’re doing is working on both aspects, the first one is the vector, we are remaining with the core belief that having dendritic cells tropic vector is key to have a low inflammatory induction of anti-tumor T cells to whatever antigen we’ve grown and so the capabilities we’re testing I think I shared this before we’re exploring, we’re ready to express more than one antigen, the ability to make it more immunogenic by co-expressing a number of [indiscernible] molecules and also the ability to potentially express or co-express for example some checkpoint inhibitor single chain antibodies. So those are the areas we’re working again with an ultimate goal to have a dendritic cell be in more immunogenic when you have been transfused with this vector. </p>
<p>And then at the context of the boost -- I am ready to tell you exactly what we are doing, but we’re exploring the ability to continue to boost and how will we do it when we have multiple antigens those are the things we’re exploring. Our goal internally as I’ve mentioned before is that by year end we’ll have a good feeling as to which of all these directions we’re pursing will come up with a more powerful second generation vector that is again loyal to the same principles and hopefully with an even stronger boost.</p>
<p>And the third question which is expression of PD-L1, I think it’s a great question, I didn’t mentioned this in my comments but it’s very clear from the science and this is why it’s important you guys keep this in mind is that a tumor that has not expressed PD-L1 as baseline in the moment you take and put T cells into that tumor because you have created another tumor immune response then that tumor is very likely to start expressing PD-L1. So, why are we so focused on combining our approaches to that checkpoint inhibitor is that even if patients that have zero baseline of PD-L1 expression in a tumor, like potentially you mentioned soft tissue sarcoma, when the moment that you start making those T cells that tumor is likely to respond very quickly because of the interferon-gamma peptide induced by those T cells to express PD-L1. So my prediction is that even PD-L1 negative patients to start with are likely going to make it in a moment you put that.</p>
<p>And if you talk to anyone in the field in a way inflammation in a tumor equals PD-L1 expression and that to me is the best biomarker. So, we are not just counting whether patients have it and then a little bit of our staff’s comment to your question and you’re right soft tissue sarcomas are a bit of a mix bag in the sense of I would say contradictory data. We have data in literature published articles where you have expression like in soft tissue sarcoma up to 50% already. But in general the concept is that it’s very depending on the soft tissue sarcoma and also very important for this approach. Many of those patients have very little inflammation, therefore very little [indiscernible] of T-cells and that would be one of reasons why in general the few data out there shows that PD1, PD-L1 are not very affective on these types of tumors which puts us in a very good situation because we will be able to hopefully induce an tumor immune response and then hopefully have the PD-L1 being upregulated and prove the concept there. That’s kind of the context of why we think it's important to have data information by the end so how that tumor look like at the end of the day when you do both things.</p>
<p><strong>Operator</strong></p>
<p>Thank you. Our next question comes from a line of Biren Amin from Jefferies. Your line is open.</p>
<p><strong><span class="question">Biren Amin </span></strong></p>
<p>Thanks guys for taking my question. Maybe I have to start with the combination CMB305 with the Genentech PD-L1 and sarcoma that you’re planning to go into for a Phase 2, what does regimen would you evaluate with the PD-L1 would you start with the mid-dose CMB305 version or would you initiate with the high dose? And then I guess more broadly, how do you think about the timing of doses of either CMB305 or LV305 with the respective PD1, PD-L1?</p>
<p><strong><span class="answer">Carlos Paya </span></strong></p>
<p>Thank you, Biren, great questions. We are right now in the process of finalizing all the exact protocols, how these would look like so I’ll kind of give you specifics and we can provide you more information may be on the next earnings call, but in general we are trying to apply the currently tested dose that Genentech deems to be safe and based on their safety data, that’s how we’re going to start. And then the plan is to continually administer the CMB305 and the PD-L1 using the currently studied and evaluated dose regulars. So in our case we’re likely going to be giving it every two weeks and I think that will then match an overlay very nicely with what our test is being studied in a clinical safety. </p>
<p>So that’s kind of where we are but I think we will be able to complete this as you know the agreement was just signed very, very recently so we are in the process of finalizing all the details and we’ll be able to provide you guys all that information hopefully in the next earnings call.</p>
<p><strong><span class="question">Biren Amin </span></strong></p>
<p>And may maybe just on NY-ESO-1 expression, can you review what the expression you are requiring for patients to enroll into the studies and also does the level of expression evolves as the tumor progresses?</p>
<p><strong><span class="answer">Carlos Paya </span></strong></p>
<p>So, again back to coming up with a final protocol, we are able to explain what we’re doing on that one but I’ll remind and ask what we’re doing with CMB305 currently that we are having a cut-off which is superior of or at least using immune chemistry superior to 1% but I can’t share with you that the big majority of patients with soft tissue we studied, they are way above that number usually in the upper percent or so 50 or higher. So that has been consistent throughout even though the cut of business you are seeing less or much lower.</p>
<p>And the second question was, sorry, which one was that?</p>
<p><strong><span class="question">Biren Amin </span></strong></p>
<p>The second question is, does the level of NY-ESO-1 expression change over time as the tumor progress. So when you’re evaluating expression, are you evaluating biopsies that are recent biopsies or are these biopsies that have been taken many months ago?</p>
<p><strong><span class="answer">Carlos Paya </span></strong></p>
<p>Yes, so I would say the literature for any cancer that's antigenic, including NY-ESO-1 has demonstrated as the tumor progresses there's higher NY-ESO-1 expression, which has always been up and under as to these are the cause or effect of the tumor getting more progressive. And so in our case again I can’t comment yet on the specifics of the Phase 2 but in our dose escalation and expansion of CMB305 we’ve been using archived biopsies so these were biopsies that were available from the patients diagnosis, some of them could be certainly as the last one that was six months but others were probably a year or two. So I would say back to that premise we potentially could be underestimating the degree of NY-ESO-1 positivity. But again to that point is that in our observation regardless of the timing the biopsies of the patients we have so far studied are usually in the high range of radio percentile from that perspective.</p>
<p><strong>Operator</strong></p>
<p>Thank you. [Operator Instructions] Our next question comes from the line of Boris Peaker from Cowen &amp; Company. Your line is open.</p>
<p><strong><span class="question">Boris Peaker </span></strong></p>
<p>Just question on the Merck and Genentech collaborations I’m just curious where these partnerships being negotiated before ASCO or were these motivated by the ASCO data?</p>
<p><strong><span class="answer">Carlos Paya </span></strong></p>
<p>We can’t comment on the due diligence that was done here, but I would say that we’ve been talking to a large number of companies everyone is very excited about what we’re doing and we have a number of interactions, but I think the ASCO data of course helps validate the approach we are doing. On paper any one of these two partners are really in sync with our thinking is that you need an immune response to a make [indiscernible] more effective. So that premise is always in there, as expected the data at ASCO in a way validates what we’re trying to do with them together. So I can’t comment specifically but I will say that ASCO data help bring this to conclusion.</p>
<p><strong><span class="question">Boris Peaker </span></strong></p>
<p>But the other thing that’s interesting here is that there doesn’t appears to be any financial considerations, could you just comment on that for both of the partnerships?</p>
<p><strong><span class="answer">Carlos Paya </span></strong></p>
<p>Yes, I have been sharing this with everyone for a long time is we’re trying to keep as much value creation for Immune Design and so we strongly believe from the beginning even if before this became I think a practice in this field if we follow very closely the HDV field and other areas of clinical collaboration. Those are the best structure for a Company of our size to be able to partner with someone that has a tool that could be useful for both, so it’s a win-win. They provide the appropriate safety and regulatory support in the sense of information and that way we don’t really give up any value from as such and so I think our goal also is to validate the field that combining a strong tumor inducing immune response with a checkpoint inhibitor will open many-many more avenues for other people to follow. But we want to be pioneers doing this and if we start providing or giving up value we’ll lose that chance. So that’s kind of how we structure this from the beginning. And I think both partners are very happy having this structure.</p>
<p><strong><span class="question">Boris Peaker </span></strong></p>
<p>And my last question on the CMB305 checkpoint inhibitor combination in sarcoma that you plan on starting. Just curious why you chose the Genentech PD-L1 drug or have you considered others or are there unique elements about the Genentech drug that makes it better combination than maybe some other options?</p>
<p><strong><span class="answer">Carlos Paya </span></strong></p>
<p>Yes, I can't comment on that I will just say that we found that the anti-PD-L1 from Genentech is a very powerful agent, yes I think it’s the right partnership, so we can't comment on the advantages of one over the other but this is how we wanted to structure the collaboration and we’re very happy to have Genentech on board.</p>
<p><strong>Operator</strong></p>
<p>Thank you. At this time, I am showing no further questions in queue. I would like to turn the call back over to Mr. Carlos Paya for closing remarks.</p>
<p><strong>Carlos Paya</strong></p>
<p>Thank you, operator and thank you all of you for your questions and it is my pleasure to share our progress with you today, including our opportunity to work with such quality partners as the ones we discussed like Merck and Genentech across both of Immune Design's immuno-oncology approaches and we look forward to updating you all throughout the rest of 2015 and beyond. So again thank you all of you for your time today.</p>
<p><strong>Operator</strong></p>
<p>Ladies and gentlemen, thank you for your participation in today’s conference. This concludes the program. You may all disconnect.</p>
</div>

<div id="article_disclaimer" class="content_part hid">
  
<p><strong>Copyright policy: </strong>All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: <strong>You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.</strong></p>

<p>THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.</p>
<p>If you have any additional questions about our online transcripts, please contact us at: <a href="mailto:transcripts@seekingalpha.com" rel="nofollow"><u>transcripts@seekingalpha.com</u></a>. Thank you!</p>

</div>

<div id="article_slice"></div>

<div class="cleaner"></div>

          </div>
          <div class="cleaner"></div>
          <div id="trafic_driver_alt_invest">
            <script>SA.Utils.Ads.marketing("trafic_driver_alt_invest", 'articles', 1, {"aid":3434746,"d":["sectors"],"t":["transcripts","us","biotechnology","healthcare","article"],"s":["imdz"],"pr":"imdz","z":1,"a":"sa-transcripts","cnt":["20","24","38","37","41"],"ldr":[]});</script>
          </div>
          <div class="cleaner"></div>
          <div class="transcript_bottom_tabs">
            <ul id="tab_cmd" style="float:left;display:none;">
              <li id="tab_single_bottom" name="tab_single" style="border-width:0px !important;" onclick='singlePageView()'><span>Single page view</span></li>
              <li id="tab_search_bottom" class="last chosen" name="tab_search" style='display:none;border-left: 1px solid #C4C4C4;'><span>Search</span></li>
            </ul>
            <div id="pag_cmd" style="display:none;">
            	<div id="tab_prev_bottom" name="tab_prev" style="display:none;float:left"><a href="javascript:void(0)" onclick="abOBJ.convert('Prev Page');trascriptNextSlice(-1)">&laquo; Previous</a>&nbsp;|&nbsp;</div>
            	<div id="tab_pagination" style="float:left"> page <span id="current_page_index">1</span> / <span id="last_page_index"></span></div>
            	<div id="next_page" style="display:none;">|&nbsp;<a href="javascript:void(0)" onclick="abOBJ.convert('Next Page');trascriptNextSlice(1)">Next »</a></div>
            </div>
            <div class="cleaner"></div>
          </div>
          <script>OpenTranscriptPage();</script>
          <div id="content_follow_up" class="transcript_follow_up">
            <div id="paging" class="transcript-paging"></div>
            <div id="article_bottom_about" class="article_bottom_units"></div>
            <div id="pro_by_ticker"></div>

            <div class="share_this_page_article_bottom">
              <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this transcript with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('Article',3434746,'http://seekingalpha.com/article/3434746-immune-designs-imdz-ceo-carlos-paya-on-q2-2015-results-earnings-call-transcript')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-text="Immune Design&#x27;s (IMDZ) CEO Carlos Paya on Q2 2015 Results - Earnings Call Transcript http://seekingalpha.com/article/3434746-immune-designs-imdz-ceo-carlos-paya-on-q2-2015-results-earnings-call-transcript?source=tweet $IMDZ" data-related="salphatrending" data-url=" " data-counturl="http://seekingalpha.com/earnings_center/all/article/3434746" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback" data-url="http://seekingalpha.com/earnings_center/all/article/3434746?source=linkedin_share"></script></span>
    <!-- facebook -->
    <span id="span_fb_widget_like" class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/earnings_center/all/article/3434746?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <div id="span_fb_widget_share" style="display: none;margin:0 10px 0 0;" class="fb-like fl" data-href="http://seekingalpha.com/earnings_center/all/article/3434746?source=facebook" data-layout="button" data-action="like" data-show-faces="false" data-share="false"></div>
    <!-- Plusone  -->
      <span id="pluszone" class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
     //FB Share button test
     $('span_fb_widget_like').hide();
     $('span_fb_widget_share').show();
     setTimeout(function(){$('span_fb_widget_share').style.background="none";}, 15000);
     $('pluszone').setStyle({'margin-left':'5px'});


    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'Article',
          article_id: '3434746'
        }
      });
    });

  </script>

  </li>
</ul>
            </div>
            <div class="cleaner"></div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>

            <div id="bottom_rta_unit" class="cb"></div>

          </div>
        </div>
    </div>
<div class="article_right_content">
	  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
    <div id='earnings_sticky'>
    	<div class="insight_back_link">
      	Back to:<br/>
      	<a href="/earnings_center/transcripts" sasource="earnings_back_link">
        	EARNINGS TRANSCRIPTS &raquo;
      	</a>
    	</div>
			<div id='ad_earnings_sticky'></div>
				<script>
				if (!is_pro){
					SA.Utils.Ads.GoogleTag.define("/6001/sek.earningscenter/articles", [[300,250],[300,600]],'ad_earnings_sticky', {"sz":"300x250,300x600","x":"x","tile":2,"d":["earningscenter","sectors"],"pos":"t","t":["articles","transcripts","us","biotechnology","healthcare","article"],"aid":3434746,"z":1,"a":"sa-transcripts","cnt":["20","24","38","37","41"],"pr":"imdz","s":"imdz"},{sticky: true});
				}
			</script>
  	</div>
	</div>
<script>
    if($$('#ads_stick .banner300x600')[0] && $('article_body_container').offsetHeight>1400) {
        if (SA.Data.User.loggedIn()) new stickyAd('ads_stick', {remove_stick_top: 650}).fixed_ads_init();
    }
</script>

</div>

  </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/21m9m" />
</div>
<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
          <a href="https://play.google.com/store/apps/details?id=com.seekingalpha.webwrapper" target="_blank" onclick="mobile_app_click()" class="google_play_mini_badge"></a>
          <a href="https://itunes.apple.com/us/app/seeking-alpha-portfolio/id552799694?mt=8" target="_blank" onclick="mobile_app_click()" class="app_store_mini_badge"></a>
      </div>
      <div class="cleaner"></div>
    </div>

     <div class="footernav_share_buttons">
   <a href="https://www.facebook.com/Seekingalpha" class="share_btn fb" sasource="footer" target="_blank"></a>
   <a href="https://twitter.com/SeekingAlpha" class="share_btn twitter" sasource="footer" target="_blank"></a>
   <a href="https://plus.google.com/+SeekingAlphaSA/" class="share_btn google" rel="publisher" sasource="footer" target="_blank"></a>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/leader-board/opinion-leaders" sasource="footer">Top Authors</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/sitemap" sasource="footer">Sitemap</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2015 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
    </div>
  </div>
  <div class="cleaner"></div>
</div>
<script>
  function mobile_app_click(){
    var location_pathname = location.pathname.split('/');
    var source = location.pathname.split('/')[1];

    if (source == '')
      source = 'home_page';
    else if (source == 'account' && location_pathname[2] == 'email_preferences')
      source = 'email_preferences';

    Mone.event('app_promo', 'footer_' + source, 'clicked');
  }
</script>

<div id="first_portfolio_unit_ref" style="display: none"> <div>
  <table id="first_portfolio_unit" style="padding-bottom: 7px !important; padding-top: 4px;">
    <thead><tr><th class="fs12">Symbol</th><th class="tr fs12">Price</th><th class="tr fs12">% Chg</th><th></th><th class="tc fs12">Remove</th><th></th></thead>
    <tbody>
        <tr id="first_portfolio_unit_cell0" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input0" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price0" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change0" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button0" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell0')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell1" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input1" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price1" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change1" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button1" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell1')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell2" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input2" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price2" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change2" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button2" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell2')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell3" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input3" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price3" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change3" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button3" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell3')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell4" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input4" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price4" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change4" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button4" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell4')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell5" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input5" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price5" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change5" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button5" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell5')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell6" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input6" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price6" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change6" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button6" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell6')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell7" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input7" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price7" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change7" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button7" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell7')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
    </tbody>
  </table>
</div>

<script>SA.Units.Portfolio.First_portfolio_unit.init('first_portfolio_symbol_input',8, 'transcript Register')</script>
</div>

<script type="text/javascript">
  Event.observe(window, 'scroll', run_article_end_mone);
  SA.Utils.Sharing.setSharingButtons('Article',ARTICLE_ID);

  if (location.href.match(/part=single/) == null){
    setRoadblockMandatoryTickers();
  	$('tab_cmd').show();
  	$('pag_cmd').show();
  }


  $('last_page_index').innerHTML = getPartialSlice(1,sliceSize,false,true,true);


  /* Roadblock test */
  function transcript_rb_show(){
    if (readCookie('user_email') && readCookie('user_email').length > 0 && !AlphaBox.isOpen) {
      SA.Utils.Popup.roadblock_login();
      createCookie('singlepageafterlogin',true);
      return;
    }

   //temporary remove iPad promo
   /*if (SA.Utils.Env.isIPad){
       ipad_roadblock_new();
   }*/
    else {
      if (document.viewport.getDimensions().height > 400){
        title = "Seeking Alpha transcribes 10,000+ earnings calls per year. For full, free access to these transcripts, please register and set up a portfolio in two easy steps:";
        createCookie('singlepageafterlogin',true);
        new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts();
      }
    }
  }
  /* Roadblock test */
  function singlePageView(){
    if (SA.Data.User.loggedIn() || SA.Pages.Article.fromInsightCenters()) {
      transcriptRedirect("single");
    } else {
      transcript_rb_show();
    }
  }

  SeekingAlpha.Initializer.onDOMLoad(function(){

    /* Roadblock test */

    SA.Pages.Article.primary = "imdz";
    SA.Pages.Article.init();

    rb = new roadblock('transcript');
    rb.additional_login_title = " for full transcript access";
    rb.register_show = transcript_rb_show;
    if (!readCookie("sessioncfr") && !SA.Pages.Article.skipFirstArticleRoadblock()) {
      if (!SA.Data.User.loggedIn() && !SA.Pages.Article.from_partner() && !SA.Pages.Article.fromEarningsCenter() && document.viewport.getDimensions().height > 400) {
        var firstPageTestValue = SA.Pages.Article.RoadblockTimeInFirstPageTest();
        if (location.href.match("page=([0-9]+)") && location.href.match("page=([0-9]+)")[1] > 1) {
          new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts();
        } else if (firstPageTestValue) {
          setTimeout(function(){ new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts(); }, firstPageTestValue * 1000);
        }
      }
    }
    if (!SA.Data.User.loggedIn() &&!SA.Pages.Article.fromInsightCenters()){
      SA.Pages.Article.hide_features_for_roadblock();
      if($('bottom_rta_unit')) {$('bottom_rta_unit').style.display = 'none';}
      if ($('tab_single_bottom')) {$('tab_single_bottom').show();}
    }
    /* Roadblock test */
  });

    SeekingAlpha.Initializer.AddAfterLoad(function(){
      SA.Pages.Article.articlePromo({"allSlugs":["imdz"],"primarySlug":"imdz"});
    });
</script>
    

<link href="//staticseekingalpha3.a.ssl.fastly.net/stylesheets/packaged/footer_packaged.css?h=1vogfdq.css" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
    window.jspell_urls = ["//staticseekingalpha3.a.ssl.fastly.net/javascripts/packaged/jspell_packaged.js?h=6a842a.js"]
    if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
        load_remote_script("//staticseekingalpha.a.ssl.fastly.net/javascripts/packaged/sa.js");
    if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
        load_remote_script("//staticseekingalpha1.a.ssl.fastly.net/javascripts/tops.js?h=uayop.js");
    Mone.renderedParams = {};
    SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('//staticseekingalpha1.a.ssl.fastly.net/stylesheets/print.css?t=1439969979')});

    function switch_status(){
        new Ajax.Request('/authentication/get_menu', {
            asynchronous:true,
            method:'get',
            onComplete: function(transport) {
                eval(transport.responseJSON.code);
            }
        });
    }
    PortfolioNotification.run();
</script>

<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>

<script type="text/javascript" src="//staticseekingalpha.a.ssl.fastly.net/pages/ads_399991.js"></script>

    <script crossorigin="use-credentials" src="//staticseekingalpha1.a.ssl.fastly.net/javascripts/packaged/footer_packaged.js?h=iyjmiy.js" type="text/javascript"></script>

<script type="application/ld+json">
    {
      "@context": "http://schema.org",
      "@type": "Organization",
      "name": "Seeking Alpha",
      "url": "http://seekingalpha.com",
      "logo": "//staticseekingalpha3.a.ssl.fastly.net/assets/social-50f1e86b5c7a0fda6a96bf2280e5360d.png",
      "sameAs" : [
        "https://plus.google.com/+SeekingAlphaSA",
        "https://twitter.com/SeekingAlpha",
        "https://www.facebook.com/Seekingalpha",
        "https://en.wikipedia.org/wiki/Seeking_Alpha",
        "https://www.linkedin.com/company/seeking-alpha"
      ]
    }
</script>
<script type="application/ld+json">
    {
       "@context": "http://schema.org",
       "@type": "WebSite",
       "url": "http://seekingalpha.com",
       "potentialAction": {
         "@type": "SearchAction",
         "target": "http://seekingalpha.com/search/?q={search_term_string}",
         "query-input": "required name=search_term_string"
       }
    }
</script>
<div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
  }
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"};
if (!$("comment_form_wrapper") && /seekingalpha\.com\/currents\/post/.test(location.href) && $("ads_and_tools")){ $("ads_and_tools").style.position = 'absolute';$("ads_and_tools").style.top="60px";$("ads_and_tools").style.right="0";};
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>
<script>
if (/article\/2953766/.test(location.href) && $('etf_hub_promo')) setTimeout(function(){ $('etf_hub_promo').style.display = 'none'},150);
</script>


    <div class="cleaner"></div>
  </body>
</html>
